InSphero acquired PhenoVista Biosciences, a cell-based assay services provider focused on high-content imaging and phenotypic assay technologies. The deal is designed to broaden InSphero’s 3D cell-based assay and organ-on-a-chip offerings for drug development, with emphasis on oncology, fibrosis, and safety assessment. InSphero said the acquisition strengthens capabilities in neuroscience and neurotoxicity testing, while expanding its U.S. footprint and complementing prior organoid and assay technology builds. The companies did not disclose deal terms. The move signals continued consolidation in phenotypic assay and imaging services—areas that help sponsors de-risk candidates when translating from mechanistic biology to functional phenotypes.